The untranslated region of (mu)-opioid receptor mRNA contributes to reduced opioid sensitivity in CXBK mice.
It is well known that there are individual differences in a sensitivity to analgesics. Several lines of evidence have suggested that the level of opioid-induced analgesia is dependent on the level of expression of the mu-opioid receptor (mu-OR). However, the molecular mechanisms underlying the diversity of the level of the opioid receptor and the opioid sensitivity among individuals remain to be elucidated. In the present study, we analyzed the opioid-receptor genes of CXBK recombinant-inbred mice, which show reduced sensitivity to opioids. Northern blotting, nucleotide sequencing, and in situ hybridization histochemical analyses demonstrated that CXBK mice possessed mu-OR mRNA with a normal coding region but an abnormally long untranslated region (UTR). In addition, the mu-OR mRNA level in CXBK mice was less than in the control mice. Next, we produced littermate mice that had inherited two copies of the wild-type mu-OR gene, had inherited two copies of the CXBK mu-OR gene, and had inherited both copies of the mu-OR genes. In these mice, inheritance of the CXBK mu-OR gene was well correlated with less mu-OR mRNA and reduced opioid effects on nociception and locomotor activity. We conclude that the CXBK mu-OR gene is responsible for the CXBK phenotypes. Because UTR differences are known to affect the level of the corresponding mRNA and protein and because UTRs are more divergent among individuals than coding regions, the present findings suggest that opioid sensitivity may vary, depending on different mu-OR levels attributable to divergent UTR of mu-OR mRNA.
Ikeda
K
K
Laboratories for Neurobiology of Emotion and Cellular Information Processing, Brain Science Institute, RIKEN, Wako, Saitama 351-0198, Japan. ikedak@prit.go.jp
Kobayashi
T
T
Ichikawa
T
T
Kumanishi
T
T
Niki
H
H
Yano
R
R
D000818:Animals; D001921:Brain / Q000378:metabolism; D004252:DNA Mutational Analysis; D018076:DNA, Complementary / Q000032:analysis / Q000235:genetics; D004351:Drug Resistance / Q000235:genetics*; D018628:Gene Dosage; D006579:Heterozygote; D006720:Homozygote; D017403:In Situ Hybridization; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D008822:Mice, Transgenic; D008970:Molecular Weight; D009020:Morphine / Q000494:pharmacology; D009043:Motor Activity / Q000187:drug effects / Q000235:genetics; D010147:Pain Measurement / Q000187:drug effects; D017354:Point Mutation; D012333:RNA, Messenger / Q000235:genetics* / Q000378:metabolism*; D022661:RNA, Untranslated / Q000235:genetics*; D017473:Receptors, Opioid, kappa / Q000819:agonists; D017450:Receptors, Opioid, mu / Q000235:genetics*
D018076:DNA, Complementary; D012333:RNA, Messenger; D022661:RNA, Untranslated; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; D009020:Morphine